Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
June 27, 2024 06:30 ET
|
Medigene AG
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
June 21, 2024 04:30 ET
|
Medigene AG
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
May 28, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
May 21, 2024 04:00 ET
|
Medigene AG
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T...
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
May 15, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to Present at Upcoming Conferences
May 07, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
May 02, 2024 04:30 ET
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
May 02, 2024 02:30 ET
|
Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG reports Financial Results and Business Update for Q1 2024
April 26, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
April 25, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...